Patrys Limited (ASX: PAB)
Health Care · Biotechnology · AU
AU$0.03
-3.57% today · -25.0% 1Y
Patrys Limited (ASX: PAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.06M and employs 15 people.
Over the last twelve months the share price has lost 25.0%, trading between 0.03 and 0.05.
Tweenvest scores Patrys Limited across four factors: quality 38/100, value 43/100, growth 0/100. Its strongest factor is value.
PAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.06M
- Revenue (TTM)
- $6.22K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 1.27
- 52-week high
- AU$0.05
- 52-week low
- AU$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 582.23M
- Employees
- 15
- Next earnings
- —
About Patrys Limited
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
- ISIN
- AU000000PAB9
- Founded
- 2006
- Listed since
- Jul 13, 2007
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Celyad Oncology SAENXTBR: CYAD | $11.43M | €0.23 | +13.50% |
| NGeneBio Co., Ltd.KOSDAQ: A354200 | $11.31M | ₩937.00 | +18.91% |
| Pharmigene, Inc.TPEX: 7595 | $11.28M | NT$7.25 | -2.03% |
| Passage Bio, Inc.NasdaqCM: PASG | $11.26M | $3.50 | -5.15% |
| IN8bio, Inc.NasdaqCM: INAB | $10.94M | $1.11 | -17.16% |
| Intensity Therapeutics, Inc.NasdaqCM: INTS | $10.94M | $3.35 | -7.71% |
| Cellectar Biosciences, Inc.NasdaqCM: CLRB | $10.78M | $1.14 | -21.38% |
| Noxopharm LimitedASX: NOX | $10.69M | AU$0.05 | -18.03% |
Figures last refreshed Oct 18, 2026.